Survodutide effect on PK of bupropion, caffeine, and midazolam in overweight/obese volunteers

Phase 1, open-label, single-arm trial of survodutide in obesity, sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve of bupropion in plasma over the time interval from 0 extrapolated to infinity, Area under the concentration-time curve of caffeine in plasma over the time interval from 0 extrapolated to infinity and 4 more. Started Oct 2024; status: completed.